Want to see DE:AAQ1 full AI Analyst Report?
AAQ1 Stock Chart & Stats
€1.46
-€0.01(-0.61%)
At close: 4:00 PM EDT
€1.46
-€0.01(-0.61%)
Day’s Range― - ―
52-Week Range€1.26 - €2.34
Previous CloseN/A
Volume51.00
Average Volume (3M)2.01K
Market Cap
€25.02M
Enterprise Value€28.81
Total Cash (Recent Filing)€286.00K
Total Debt (Recent Filing)€3.97M
Price to Earnings (P/E)―
Beta-0.24
Next Earnings
Aug 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding14,716,976
10 Day Avg. Volume998
30 Day Avg. Volume2,009
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.27
Price to Sales (P/S)1.58
P/FCF Ratio-9.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAn approximately 82% gross margin shows that the company retains substantial value after direct product costs. This provides a sound economic base for covering operating expenses and suggests that, if sales scale or costs improve, existing product economics could support better profitability over the next several quarters.
Manageable LeverageLow debt relative to equity limits the immediate burden of interest and principal obligations, while positive equity provides a financial cushion. This relatively conservative capital structure preserves more flexibility to fund operations, manage losses, or pursue growth without relying heavily on additional borrowing.
Two-Part Product Revenue ModelThe company addresses orthopedic procedures through both implant products and the instrument systems used to place them. This gives its commercial offering broader relevance across the surgical workflow and creates more than one product category through which hospitals, distributors, and healthcare partners can engage.
Bears Say
Persistent Net LossesOngoing net losses indicate that strong gross profitability has not yet translated into a sustainable earnings model. Continued losses can erode equity over time, restrict internally funded investment, and make the company more dependent on operational improvement or external financing to support its business.
Continued Cash BurnNegative operating and free cash flow show that the core business is not currently self-funding, even before considering broader capital allocation. Persistent cash consumption increases the importance of reversing operating losses and can reduce financial flexibility if funding needs continue over the coming quarters.
Weakening Revenue MomentumThe TTM revenue decline signals weakening demand or execution momentum after a period of broadly stable sales. Slower top-line performance makes it harder to absorb the existing operating cost base, delays the path to break-even, and limits the ability to leverage the company’s high gross margin.
AAQ1 FAQ
What was aap Implantate AG’s price range in the past 12 months?
aap Implantate AG lowest stock price was €1.26 and its highest was €2.34 in the past 12 months.
What is aap Implantate AG’s market cap?
aap Implantate AG’s market cap is €25.02M.
When is aap Implantate AG’s upcoming earnings report date?
aap Implantate AG’s upcoming earnings report date is Aug 18, 2027 which is in 328 days.
How were aap Implantate AG’s earnings last quarter?
aap Implantate AG released its earnings results on Aug 17, 2026. The company reported -€0.078 earnings per share for the quarter.
Is aap Implantate AG overvalued?
According to Wall Street analysts aap Implantate AG’s price is currently Overvalued.
Does aap Implantate AG pay dividends?
aap Implantate AG does not currently pay dividends.
What is aap Implantate AG’s EPS estimate?
aap Implantate AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does aap Implantate AG have?
aap Implantate AG has 14,716,976 shares outstanding.
What happened to aap Implantate AG’s price movement after its last earnings report?
aap Implantate AG reported an EPS of -€0.078 in its last earnings report. Following the earnings report the stock price went up 5.333%.
Which hedge fund is a major shareholder of aap Implantate AG?
Currently, no hedge funds are holding shares in DE:AAQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aap Implantate Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
aap Implantate AG
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
Technical Analysis
Carl Zeiss Meditec
―
Eckert & Ziegler Strahlen und Medizintechnik
―
Geratherm Medical
―
MagForce AG
―
elexxion AG
―